Synexa Life Sciences (Pty)
Synexa Life Sciences (Pty) is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
A Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029, as Monotherapy and in Combination with Standard Therapies in Participants with Relapsed or Refractory, or Newly Diagnosed Acute Myeloid Leukemia (AML) with NPM1 Mutations, KMT2A or NUP98 Rearrangements
Sponsor Charm Therapeutics Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
A randomized, double-blind, parallel-group, active-controlled comparative study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of LY06006 compared with EU-Prolia in postmenopausal women with osteoporosis
Sponsor Shandong Boan Biotechnology Co. Ltd.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The study randomized 530 participants, exceeding the planned sample size of 524.
- The study was conducted at 39 sites in Bulgaria (4), the Czech Republic (2), Poland (19), Japan (11), and the United States (3).
- The Czech Republic applied a country-specific upper age limit of 75 years, whereas the overall eligibility range was 55 to 90 years.
These findings describe the trial, not the service provider’s performance or responsibility.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
Sponsor Ventus Therapeutics U.S. Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomised, Placebo-Controlled, 3-Arm, Double-Blind, Multicentre, Phase 4 Study to Assess the Efficacy of OM-85 (Broncho Vaxom) Short- and Long-Term Treatment vs. Placebo in the Prevention of Respiratory Tract Infections in Children Aged Between 6 Months and 5 Years with Wheezing Lower Respiratory Illness
Sponsor OM Pharma SA
- Start (EU)
- Latest update
- Estimated end
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo given in Children Aged 6 Months to 5 Years with Recurrent Wheezing
Sponsor OM Pharma SA
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Synexa Life Sciences (Pty)?
The 2026-10-09 snapshot links Synexa Life Sciences (Pty) to 5 distinct CTIS trials. Recorded services include Laboratory services, PK, ADA and Nab Assay. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Synexa Life Sciences (Pty)?
The most frequently recorded therapeutic areas are Respiratory, Dermatology, Endocrinology, Haematological Malignancies. Recorded phases include Phase 2, Phase 1, Phase 3, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Synexa Life Sciences (Pty) conducted?
The linked trials record locations in 9 countries, including Poland, Hungary, Bulgaria, Czechia, Germany. These are trial locations, not confirmed office locations or countries where Synexa Life Sciences (Pty) delivered services.
What can this page tell me about Synexa Life Sciences (Pty)'s trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Synexa Life Sciences (Pty). Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Synexa Life Sciences (Pty) Ltd
- Synexa Life Sciences (Pty) Ltd.